Cargando…

Response to ‘Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis’

Detalles Bibliográficos
Autores principales:	Vastesaeger, Nathan, Fautrel, Bruno, Smolen, Josef
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4475331/ https://www.ncbi.nlm.nih.gov/pubmed/26091916 http://dx.doi.org/10.1186/s13075-015-0680-8

Ejemplares similares

Response to ‘Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis’ – authors’ reply
por: Markusse, Iris M., et al.
Publicado: (2015)

Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis
por: Markusse, Iris M, et al.
Publicado: (2014)

Response to the commentary 'Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind'
por: Vander Cruyssen, Bert, et al.
Publicado: (2006)

Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects
por: Smolen, Josef S, et al.
Publicado: (2021)

The science of rheumatoid arthritis: a prelude
por: Smolen, Josef S
Publicado: (2005)

Autoantibodies in rheumatoid arthritis and their clinical significance
por: Steiner, Günter, et al.
Publicado: (2002)

Developments in the clinical understanding of rheumatoid arthritis
por: Smolen, Josef S, et al.
Publicado: (2009)

Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor
por: Tan, Eng M., et al.
Publicado: (2016)

Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort
por: Lukas, Cédric, et al.
Publicado: (2019)

Candidate Markers for Stratification and Classification in Rheumatoid Arthritis
por: Bader, Lucius, et al.
Publicado: (2019)

Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis
por: Landewé, Robert, et al.
Publicado: (2015)

Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials
por: Aletaha, Daniel, et al.
Publicado: (2015)

Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease
por: Avouac, Jérôme, et al.
Publicado: (2020)

Identifying patients with rheumatoid arthritis with moderate disease activity at risk of significant radiographic progression despite methotrexate treatment
por: Fautrel, B, et al.
Publicado: (2015)

Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate
por: Smolen, Josef S, et al.
Publicado: (2018)

Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials
por: Smolen, Josef, et al.
Publicado: (2019)

Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease
por: Smolen, Josef S, et al.
Publicado: (2016)

Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs
por: Radner, Helga, et al.
Publicado: (2014)

Pharmacogenomics of Anti-TNF Treatment Response Marks a New Era of Tailored Rheumatoid Arthritis Therapy
por: Wysocki, Tomasz, et al.
Publicado: (2022)

The diagnostic significance of autoantibodies in patients with very early rheumatoid arthritis
por: Nell, V, et al.
Publicado: (2003)

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)

Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients
por: Radner, Helga, et al.
Publicado: (2015)

Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study
por: Beydon, Maxime, et al.
Publicado: (2023)

Autoantibodies in very early rheumatoid arthritis: diagnostic tools or pathogenic players?
por: Steiner, G, et al.
Publicado: (2003)

Response to ‘Body mass index and the risk of rheumatoid arthritis: a systematic review and dose–response meta-analysis’
por: Liu, Yang, et al.
Publicado: (2015)

Value of self-performed joint counts in rheumatoid arthritis patients near remission
por: Radner, Helga, et al.
Publicado: (2012)

Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort
por: Fautrel, Bruno, et al.
Publicado: (2012)

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
por: Smolen, Josef S., et al.
Publicado: (2017)

Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts
por: Bouget, Vincent, et al.
Publicado: (2022)

Does the multi-biomarker disease activity score have diagnostic value in early rheumatoid arthritis and unclassified arthritis?
por: Maijer, Karen I, et al.
Publicado: (2015)

Remission by composite scores in rheumatoid arthritis: are ankles and feet important?
por: Kapral, Theresa, et al.
Publicado: (2007)

Elicitation of Rheumatologist Preferences for the Treatment of Patients with Rheumatoid Arthritis After the Failure of a First Conventional Synthetic Disease-Modifying Anti-Rheumatic Agent
por: Senbel, Eric, et al.
Publicado: (2021)

Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?
por: Jani, Meghna, et al.
Publicado: (2019)

The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?
por: Smolen, Josef S, et al.
Publicado: (2008)

Role of carotid ultrasonography in the evaluation of cardiovascular risk in patients with rheumatoid arthritis
por: Gonzalez-Gay, Miguel A, et al.
Publicado: (2010)

Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis
por: Kerschbaumer, Andreas, et al.
Publicado: (2020)

Post-Chikungunya Rheumatoid Arthritis, Saint Martin
por: Foissac, Maud, et al.
Publicado: (2015)

Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis
por: Studenic, Paul, et al.
Publicado: (2021)

Response to: ‘Body mass index and the risk of rheumatoid arthritis: a systematic review and dose–response meta-analysis’ - authors’ reply
por: Qin, Baodong, et al.
Publicado: (2015)

Response to Comment on “Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth”
por: McAnally, Heath B., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qoqlguo5kavhqe7fadurs41fig